News Articles for Botanix Pharmaceuticals

This week's Bulls N' Bears ASX Runners of the Week is… Yandal Resources, after the company identified a gold discovery of potentially massive scale in one of WA's prolific gold belts. Imagion shot up on positive talks with the US FDA on its Phase 2 breast cancer imaging technology, Falcon intercepted some of the highest grade gold in Australian drilling this year and Bayan scooped up a strategic rare earths project next to the world-class Mountain Pass mine.

Vince Ippolito chaired Botanix will ask investors for $40 million as it eyes an expansion of its US offerings following a successful first few months in the market.

ASX-listed Botanix has shipped the first batch of Sofdra prescriptions, marking a milestone moment as it shifts towards becoming a revenue generating pharmaceuticals company.

Leederville-based medical dermatology company Botanix has announced it will tap investors for $70 million to fund the launch of its recently US Food and Drug Administration approved Sofdra gel.

Leederville-based medical dermatology company Botanix has received US Food and Drug Administration approval for its Sofdra gel, used to treat excessive underarms sweating.

Clinical dermatology company Botanix Pharmaceuticals is tapping investors for $13.5 million to help fund the commercial launch of its lead treatment.

Our board moves wrap includes Jeremy Robinson, Howie McKibbon, Simon Acomb, Ranko Matic, Vicki Krause, Bob McKinnon, Margaret Kennedy, Michelle Tierney, Greg Wall, and Tony Lennon.

Botanix Pharmaceuticals has secured commitments from investors and is on track to raise $12.5 million via a placement to fund the buyout of financial obligations owed to another company.

Our board moves wrap includes Susan Park, Simon Robertson, Richard Clayton, Mike Brook, Matthew Smith, Thomas Hanly, and Denning Chong.

Botanix Pharmaceuticals has secured commitments from investors to raise $10 million through a placement to develop its leading product.

The commercial side of life sciences may have reached a critical mass in WA.

A Perth-based pharmaceutical founded by 40under40 winner Matt Callahan has acquired its first product in a bid to manoeuvre from research and development status to revenue-generating.

Our board moves wrap includes Daniel Sharp and Damon Cox.

Our board moves wrap includes Brian Thomas, Annie Guo, Peter Ingram, Michael Thurn, Jeremy Whybrow, Patrick Glovac, and Vaughn Taylor.

The strong growth of the medicinal cannabis industry will need to be supported by research for the sector to take the next step.

Perth's largest drug testing company plans to nearly double capacity as WA attracts attention from global pharmaceutical companies.

Matt Callahan has re-joined the board of Botanix Pharmaceuticals as an executive director following the decision by Robert Towner to step down as non-executive director.

Shares in Bentley-based medical cannabis company Botanix Pharmaceuticals have nearly halved, after it released the results of its clinical trial for acne treatment.

Our daily board moves wrap includes Matt Callahan, Simon Paull, Alan Armstrong, David Rich, and Patrick Glovac.

Our weekly appointment wrap includes Eric Lumsden, John Langoulant, Michael Court, Nicole Lockwood, Terry Agnew, Kerryl Bradshaw, Andrea Sutton, Wayne Zekulich, Keith Hirschman, Tony Sheard, Alex Ogg, Nicholas Chapple, Paul Pryde, Shane Ogilvie, Saschelle Blake, Brett Heather, Richard Peterson, and Howie McKibbon.

Botanix Pharmaceuticals is set to raise $40 million via a share placement, less than two months after it released studies suggesting its cannabis compound could be used as an antimicrobial to mitigate superbugs.

This weekly board moves wrap includes Vince Ippolito, Stewart Washer, Matthew Madden, Jason Stirbinskis, Rob McDonald, Evan Cranston, Tolga Kumova, Dror Nagel, Leigh Junk, Maggie Niewidok, Justin Mouchacca, Laurie Marsland, Michael Hardy, Matthew Carr, Cameron Henry, Robert Sckalor, and David McArthur.

Botanix Pharmaceuticals has appointed Vince Ippolito as its president in the US, and subject to shareholder approval, he will also assume the role of executive chairman for the company.

Perth's business community was shocked today to learn of the sudden passing of Graham Griffiths, who was chairman of five technology companies and had been a mentor to many people in the tech sector.

Two local biotech companies have announced capital raisings today, with Botanix Pharmaceuticals tapping investors for $8 million, while Roto-Gro International has boosted its coffers with a $4.5 million raising.

Local startups and young technology companies registered a big decline in funds raised in the March quarter compared to December, according to the latest report from tech sector analysts Techboard.

Okapi Resources Limited (ASX:“OKR”) (“Okapi” & “Company”) is pleased to announce that, further to its announcement of 24 January 2018, it has completed the issue of 2,142,857 fully paid ordinar

Medical dermatology company Botanix Pharmaceuticals has raised $15 million through a strongly supported share placement, with the proceeds set to be spent on developing its lead product for acne.

Shares in medical dermatology company Botanix Pharmaceuticals, led by Perth-based chairman Graham Griffiths and executive director Matt Callahan, have jumped more than 20 per cent today after the company announced successful results from an acne patient study.

Biotech Botanix Pharmaceuticals has raised $7.4 million in a placement of new shares to help it fund the further development of its dermatology products that contain a synthetic form of the cannabis compound, cannabidiol.

Medical dermatology company Botanix Pharmaceuticals has enjoyed healthy gains on its first day of trading on the ASX, after completing a reverse takeover of Bone Medical.